{"transactions":[{"id":765983,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001639860-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000163986026000005/ownership.xml","form_type":"4"}},{"id":946629,"issuer":{"id":5028,"kind":"organization","name":"Silence Therapeutics plc"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief R&D Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2026-01-06T21:15:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":2.05,"expiration_date":"2036-01-02","underlying":"Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001639860-26-000002","document":"form4-01062026_040105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479615/000163986026000002/form4-01062026_040105.xml","form_type":"4"}},{"id":1137207,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T20:42:58.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-076408","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076408/ownership.xml","form_type":"4"}},{"id":1310493,"issuer":{"id":5028,"kind":"organization","name":"Silence Therapeutics plc"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief R&D Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2025-01-06T21:15:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date."}],"balance_after":285000,"derivative":{"exercise_price":2.4,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001415889-25-000745","document":"form4-01062025_040106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479615/000141588925000745/form4-01062025_040106.xml","form_type":"4"}},{"id":1403634,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T21:38:57.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":22000,"derivative":{"exercise_price":26.42,"expiration_date":"2034-09-15","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-107900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024107900/ownership.xml","form_type":"4"}},{"id":2224966,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":102801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":102801},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224965,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":189201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary Shares","underlying_shares":189201},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224964,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":59731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":51.73,"exercise_date":"2021-01-03","expiration_date":"2027-01-03","underlying":"Ordinary Shares","underlying_shares":59731},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224963,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":59731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":51.73,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Ordinary Shares","underlying_shares":59731},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224962,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":22288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":72.61,"exercise_date":"2017-01-04","expiration_date":"2026-01-04","underlying":"Ordinary Shares","underlying_shares":22288},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224961,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":11275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"derivative":{"exercise_price":120.27,"exercise_date":"2016-07-01","expiration_date":"2025-07-01","underlying":"Ordinary Shares","underlying_shares":11275},"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":2224960,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2022-06-21T22:10:54.000Z","date":"2022-06-16","kind":"disposition_to_issuer","acquired":false,"shares":72637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (\"Mallinckrodt\"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the \"Bankruptcy Code\") in the U.S. Bankruptcy Court for the District of Delaware (the \"Bankruptcy Court\"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the \"Plan\"), and on June 16, 2022 (the \"Effective Date\"), the Plan became effective and Mallinckrodt emerged from bankruptcy."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the \"Ordinary Shares\"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-023426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000089924322023426/doc4.xml","form_type":"4"}},{"id":3182394,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2020-04-03T20:45:34.000Z","date":"2020-04-02","kind":"tax_withholding","acquired":false,"shares":3022,"price":1.8,"value":5439.6,"ownership":{"direct":true},"balance_after":72637,"source":{"system":"sec-edgar","filing":"0000950138-20-000204","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013820000204/edgar.xml","form_type":"4"}},{"id":3182393,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2020-04-03T20:45:34.000Z","date":"2020-04-01","kind":"tax_withholding","acquired":false,"shares":1924,"price":1.93,"value":3713.32,"ownership":{"direct":true},"balance_after":75659,"source":{"system":"sec-edgar","filing":"0000950138-20-000204","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013820000204/edgar.xml","form_type":"4"}},{"id":3316169,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2020-01-08T00:57:06.000Z","date":"2020-01-04","kind":"tax_withholding","acquired":false,"shares":284,"price":3.26,"value":925.84,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 505 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":77583,"source":{"system":"sec-edgar","filing":"0000950138-20-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013820000017/edgar.xml","form_type":"4"}},{"id":3316168,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2020-01-08T00:57:06.000Z","date":"2020-01-03","kind":"tax_withholding","acquired":false,"shares":883,"price":3.36,"value":2966.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 505 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":77867,"source":{"system":"sec-edgar","filing":"0000950138-20-000017","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013820000017/edgar.xml","form_type":"4"}},{"id":3467331,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2019-07-03T11:54:52.000Z","date":"2019-07-01","kind":"tax_withholding","acquired":false,"shares":285,"price":9.09,"value":2590.65,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,204 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":78245,"source":{"system":"sec-edgar","filing":"0000950138-19-000370","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000370/edgar.xml","form_type":"4"}},{"id":3563759,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-03T21:46:22.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":102801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":102801,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":102801},"source":{"system":"sec-edgar","filing":"0000950138-19-000221","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000221/edgar.xml","form_type":"4"}},{"id":3563758,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2019-04-03T21:46:22.000Z","date":"2019-04-02","kind":"tax_withholding","acquired":false,"shares":3103,"price":22.8,"value":70748.4,"ownership":{"direct":true},"balance_after":77326,"source":{"system":"sec-edgar","filing":"0000950138-19-000221","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000221/edgar.xml","form_type":"4"}},{"id":3563757,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2019-04-03T21:46:22.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":22462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020."}],"balance_after":80429,"source":{"system":"sec-edgar","filing":"0000950138-19-000221","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000221/edgar.xml","form_type":"4"}},{"id":3701606,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2019-01-07T23:02:55.000Z","date":"2019-01-04","kind":"tax_withholding","acquired":false,"shares":431,"price":17.21,"value":7417.51,"ownership":{"direct":true},"balance_after":57967,"source":{"system":"sec-edgar","filing":"0000950138-19-000023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000023/edgar.xml","form_type":"4"}},{"id":3701605,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2019-01-07T23:02:55.000Z","date":"2019-01-03","kind":"tax_withholding","acquired":false,"shares":980,"price":16.14,"value":15817.2,"ownership":{"direct":true},"balance_after":58398,"source":{"system":"sec-edgar","filing":"0000950138-19-000023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000023/edgar.xml","form_type":"4"}},{"id":3874043,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2018-07-03T20:29:37.000Z","date":"2018-07-01","kind":"tax_withholding","acquired":false,"shares":285,"price":18.66,"value":5318.1,"ownership":{"direct":true},"balance_after":59378,"source":{"system":"sec-edgar","filing":"0000950138-18-000463","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000463/edgar.xml","form_type":"4"}},{"id":3969074,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2018-04-04T22:11:14.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":189201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal annual installments beginning April 2, 2019."}],"balance_after":189201,"derivative":{"exercise_price":13.8,"exercise_date":"2019-04-02","expiration_date":"2028-04-02","underlying":"Ordinary Shares","underlying_shares":189201},"source":{"system":"sec-edgar","filing":"0000950138-18-000313","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000313/edgar.xml","form_type":"4"}},{"id":3969073,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2018-04-04T22:11:14.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":36232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 842 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan."}],"balance_after":59663,"source":{"system":"sec-edgar","filing":"0000950138-18-000313","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000313/edgar.xml","form_type":"4"}},{"id":4105038,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2018-01-06T00:33:25.000Z","date":"2018-01-04","kind":"tax_withholding","acquired":false,"shares":507,"price":23.4,"value":11863.8,"ownership":{"direct":true},"balance_after":22589,"source":{"system":"sec-edgar","filing":"0000950138-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000047/edgar.xml","form_type":"4"}},{"id":4105037,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2018-01-06T00:33:25.000Z","date":"2018-01-03","kind":"tax_withholding","acquired":false,"shares":1136,"price":23.51,"value":26707.36,"ownership":{"direct":true},"balance_after":23096,"source":{"system":"sec-edgar","filing":"0000950138-18-000047","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000047/edgar.xml","form_type":"4"}},{"id":4164978,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2017-11-13T22:37:19.000Z","date":"2017-11-13","kind":"purchase","acquired":true,"shares":2000,"price":21.96,"value":43920.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 246 shares acquired between April 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan."}],"balance_after":24232,"source":{"system":"sec-edgar","filing":"0000950138-17-000758","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000758/edgar.xml","form_type":"4"}},{"id":4263294,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2017-07-05T20:17:30.000Z","date":"2017-07-01","kind":"tax_withholding","acquired":false,"shares":310,"price":44.81,"value":13891.1,"ownership":{"direct":true},"balance_after":21986,"source":{"system":"sec-edgar","filing":"0000950138-17-000516","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000516/edgar.xml","form_type":"4"}},{"id":4285046,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2017-06-12T20:16:06.000Z","date":"2017-06-09","kind":"purchase","acquired":true,"shares":1000,"price":39.881,"value":39881.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $39.88 to $39.89, inclusive. Mr. Romano will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 273 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan."}],"balance_after":22296,"source":{"system":"sec-edgar","filing":"0000950138-17-000476","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000476/edgar.xml","form_type":"4"}},{"id":4453357,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2017-02-13T13:46:17.000Z","date":"2017-02-10","kind":"purchase","acquired":true,"shares":1000,"price":49.68,"value":49680.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 180 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan."}],"balance_after":21023,"source":{"system":"sec-edgar","filing":"0000950138-17-000152","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000152/edgar.xml","form_type":"4"}},{"id":4501695,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2017-01-05T02:18:21.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":59731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in their entirety on January 3, 2021."}],"balance_after":59731,"derivative":{"exercise_price":51.73,"exercise_date":"2021-01-03","expiration_date":"2027-01-03","underlying":"Ordinary Shares","underlying_shares":59731},"source":{"system":"sec-edgar","filing":"0000950138-17-000025","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000025/edgar.xml","form_type":"4"}},{"id":4501694,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2017-01-05T02:18:21.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":59731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal annual installments beginning January 3, 2018."}],"balance_after":59731,"derivative":{"exercise_price":51.73,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Ordinary Shares","underlying_shares":59731},"source":{"system":"sec-edgar","filing":"0000950138-17-000025","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000025/edgar.xml","form_type":"4"}},{"id":4501693,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":44739,"kind":"person","name":"Romano Steven J.","position":1,"cik":"0001639860","reported_name":"Romano Steven J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Exec. VP & Chief Sci. Ofcr"}}],"security":"Ordinary Shares","published_at":"2017-01-05T02:18:21.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":10633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 197 shares acquired on September 30, 2016 under the Mallinckrodt employee stock purchase plan."}],"balance_after":19843,"source":{"system":"sec-edgar","filing":"0000950138-17-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013817000025/edgar.xml","form_type":"4"}}]}